Rheumatoid Arthritis News

The European Commission has approved the subcutaneous formulation of Celltrion’s infliximab biosimilar for adult patients with active rheumatoid arthritis who have had an inadequate response to a prior DMARD, as well as patients with severe, active and progressive disease not previously treated with DMARDs, according to a manufacturer press release.

ATLANTA — The presence of tenosynovitis, along with an anti-filaggrin peptide, were associated with the development of rheumatoid arthritis in a cohort of participants who underwent anti-citrullinated protein antibody testing, according to a speaker at ACR/ARP 2019.

ATLANTA — Although disease flares were common among patients with rheumatoid arthritis who received immune checkpoint inhibitors to treat concomitant malignancies, the symptoms were mostly manageable and few patients discontinued the treatment, according to findings presented at the 2019 ACR/ARP Annual Meeting.

ATLANTA — A multibiomarker disease activity blood test predicted radiographic progression and cardiovascular outcomes in patients with rheumatoid arthritis, according to findings presented in two posters at ACR/ARP 2019.

ATLANTA — Biologic DMARDs were as efficacious among patients with rheumatoid arthritis aged 60 years and older at disease onset as it was among younger patients, with comparable rates of drug maintenance and adverse event discontinuation between the two groups, according to findings presented at the 2019 ACR/ARP Annual Meeting.

ATLANTA — An intervention bundle reminding patients with rheumatoid arthritis and juvenile idiopathic arthritis of the benefits of influenza vaccination was associated with improved vaccine coverage, according to findings presented at ACR/ARP 2019.

The American College of Rheumatology has added the Vectra blood test, developed by Myriad Genetics, to its list of recommended disease activity measures for rheumatoid arthritis, according to a press release.

ATLANTA — The use of either non-TNF inhibitor biologics or tofacitinib for chronic inflammatory diseases during pregnancy did not significantly increase risk for serious infections among infants, according to findings presented at the 2019 ACR/ARP Annual Meeting.

ATLANTA — A vast majority of patients with a cross-section of rheumatic diseases reported that pain, fatigue and mental health issues were those they would like researchers to track, according to a speaker at ACR/ARP 2019.

The FDA has approved Abrilada, a biosimilar to Humira, making it the fifth biosimilar to the reference drug and 25th biosimilar overall to gain approval in the United States, according to an agency press release.